Literature DB >> 15863497

Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases.

Jee Young Sung1, Sung Min Park, Choong-Hwan Lee, Ji Won Um, Hyun Jung Lee, Jongsun Kim, Young J Oh, Seung-Taek Lee, Seung R Paik, Kwang Chul Chung.   

Abstract

Although alpha-synuclein is the main structural component of the insoluble filaments that form Lewy bodies in Parkinson disease (PD), its physiological function and exact role in neuronal death remain poorly understood. In the present study, we examined the possible functional relationship between alpha-synuclein and several forms of matrix metalloproteinases (MMPs) in the human dopaminergic neuroblastoma (SK-N-BE) cell line. When SK-N-BE cells were transiently transfected with alpha-synuclein, it was secreted into the extracellular culture media, concomitantly with a significant decrease in cell viability. Also the addition of nitric oxide-generating compounds to the cells caused the secreted alpha-synuclein to be digested, producing a small fragment whose size was similar to that of the fragment generated during the incubation of alpha-synuclein with various MMPs in vitro. Among several forms of MMPs, alpha-synuclein was cleaved most efficiently by MMP-3, and MALDI-TOF mass spectra analysis showed that alpha-synuclein is cleaved from its C-terminal end with at least four cleavage sites within the non-Abeta component of AD amyloid sequence. Compared with the intact form, the protein aggregation of alpha-synuclein was remarkably facilitated in the presence of the proteolytic fragments, and the fragment-induced aggregates showed more toxic effect on cell viability. Moreover, the levels of MMP-3 were also found to be increased significantly in the rat PD brain model produced by the cerebral injection of 6-hydroxydopamine into the substantia nigra. The present study suggests that the extracellularly secreted alpha-synuclein could be processed via the activation of MMP-3 in a selective manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863497     DOI: 10.1074/jbc.M503341200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  84 in total

1.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 2.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

3.  PINK1 stimulates interleukin-1β-mediated inflammatory signaling via the positive regulation of TRAF6 and TAK1.

Authors:  Hyun Jung Lee; Sung Hee Jang; Hyeyoung Kim; Joo Heon Yoon; Kwang Chul Chung
Journal:  Cell Mol Life Sci       Date:  2012-05-29       Impact factor: 9.261

Review 4.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 5.  The role of exosomes in the processing of proteins associated with neurodegenerative diseases.

Authors:  Laura J Vella; Robyn A Sharples; Rebecca M Nisbet; Roberto Cappai; Andrew F Hill
Journal:  Eur Biophys J       Date:  2007-12-07       Impact factor: 1.733

Review 6.  Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.

Authors:  Seung-Jae Lee
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

7.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

Review 8.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 9.  Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases.

Authors:  He-Jin Lee; Eun-Jin Bae; Seung-Jae Lee
Journal:  Nat Rev Neurol       Date:  2014-01-28       Impact factor: 42.937

10.  Transmission of Soluble and Insoluble α-Synuclein to Mice.

Authors:  Daryl Rhys Jones; Marion Delenclos; AnnMarie T Baine; Michael DeTure; Melissa E Murray; Dennis W Dickson; Pamela J McLean
Journal:  J Neuropathol Exp Neurol       Date:  2015-12       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.